Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

NEXSTIM PLC PUBLISHES 2017 ANNUAL REPORT


Posted on: 07 Mar 18

Company announcement, Helsinki, 7 March 2018 at 9:00 AM

NEXSTIM PLC PUBLISHES 2017 ANNUAL REPORT

Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company"), a neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic and diagnostic application, announces the publication of its 2017 Annual Report.  These documents are available on the "Investor Relations" section of the Company's website at www.nexstim.com.

The Annual Report includes the Report of the Board of Directors, the Financial Statements and Consolidated Financial Statements and the Auditor's Report. A copy of the Annual Report is attached to this announcement.

NEXSTIM PLC
Martin Jamieson, Chairman and CEO

Further information is available on the website www.nexstim.com or by telephone: 

Nexstim                                              +447715163942
Martin Jamieson, Chairman and CEO martin.jamieson@nexstim.com
                                                                                                                                                      
UB Securities Oy (Certified Adviser) +358 (0)9 2538 0246

Citigate Dewe Rogerson           +44 (0)207 2822949
David Dible/Isabelle Andrews/Shabnam Bashir  david.dible@citigatedewerogerson.com

About Nexstim Plc
Nexstim is a neuromodulation company developing and marketing pioneering navigated non-invasive brain stimulation systems for both therapeutic (NBT® system) and diagnostic (NBS system) applications. Nexstim's NBS system is the only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for the pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed the Navigated Brain Therapy (NBT®) which is CE marked in Europe for the treatment of stroke, major depression and chronic neuropathic pain.

Nexstim has received clearance from the FDA for marketing and commercial distribution of its NBT® system for the treatment of Major Depressive Disorder (MDD) and looks forward to introducing the NBT® system for this important indication during Q2 2018.

The NBT® system is currently in a 60 patient, supplemental Phase III study, E-FIT trial, for its use in stroke rehabilitation. The trial is expected to complete in mid-2018, allowing Nexstim to file for FDA clearance. FDA clearance would allow Nexstim to start marketing and selling its NBT® system for stroke rehabilitation in the USA.

Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden. For more information please visit www.nexstim.com

Attachment:

http://www.globenewswire.com/NewsRoom/AttachmentNg/f2cfa7b5-f809-46e3-844f-389c2b556d7c

GlobeNewswire
globenewswire.com

Last updated on: 07/03/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.